AVITA Therapeutics States 1st Patient Enrolled in Pivotal Study Evaluating the RECELL System for Repigmentation of Stable Vitiligo

AVITA Therapeutics Chief Executive Officer, “The initiation of the vitiligo clinical study is a milestone in advancing AVITA Therapeutic’s pipeline to leverage the utility and full potential of our innovative RECELL technology platform to address unmet medical needs in dermatological applications.